Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking.

Journal of biological engineering·2026
Same author

Correction: Enhancing glioblastoma therapy: unveiling synergistic anticancer effects of Onalespib - radiotherapy combination therapy.

Frontiers in oncology·2026
Same author

Tumour accumulation of anti-carcinoembryonic antigen affibody-albumin-binding domain fusion depends on domains' order.

International journal of biological macromolecules·2026
Same author

The Use of Glycine-Containing Peptide-Based Chelators for Labeling with <sup>99m</sup>Tc Improves the Imaging Properties of EpCAM-Targeting Designed Ankyrin Repeat Ec1.

Molecular pharmaceutics·2026
Same author

Efficient <sup>68</sup>Ga Labeling of a B7-H3-Targeting Affibody Molecule via Acyclic Tris(hydroxypyridinone) Chelator: Effects on Biodistribution in a Preclinical Model.

International journal of molecular sciences·2026
Same author

Exploring the theranostic potential of two metabolically stable GRPR-targeting peptides labelled with Ga-68 for PET imaging.

EJNMMI radiopharmacy and chemistry·2026

Related Experiment Video

Updated: Jul 8, 2026

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

Differences in radiosensitivity between three HER2 overexpressing cell lines.

Ann-Charlott Steffen1, Lovisa Göstring, Vladimir Tolmachev

  • 1Department of Oncology, Radiology and Clinical Immunology, Rudbeck Laboratory, Uppsala University, Uppsala, 751 85, Sweden.

European Journal of Nuclear Medicine and Molecular Imaging
|January 15, 2008
PubMed
Summary
This summary is machine-generated.

HER2-overexpressing breast cancer cells show varying inherent radiosensitivity to both conventional and alpha-particle radiation. This radiosensitivity difference is linked to affibody molecule internalization and cell nucleus size, impacting targeted radionuclide therapy effectiveness.

More Related Videos

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
12:35

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines

Published on: September 3, 2016

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Related Experiment Videos

Last Updated: Jul 8, 2026

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System
11:31

Determining Optimal Cytotoxic Activity of Human Her2neu Specific CD8 T cells by Comparing the Cr51 Release Assay to the xCELLigence System

Published on: August 8, 2012

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines
12:35

Comparison of Three Different Methods for Determining Cell Proliferation in Breast Cancer Cell Lines

Published on: September 3, 2016

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
09:45

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines

Published on: August 21, 2019

Area of Science:

  • Oncology
  • Radiation Biology
  • Molecular Imaging

Background:

  • Human Epidermal growth factor Receptor 2 (HER2) is a key target in breast cancer therapy.
  • Resistance to Herceptin(R) highlights the need for alternative therapeutic strategies, such as radionuclide therapy.
  • Understanding inherent tumor cell radiosensitivity is crucial for optimizing treatment outcomes.

Purpose of the Study:

  • To investigate the inherent radiosensitivity of HER2-overexpressing breast cancer cell lines.
  • To compare the response of these cell lines to low and high Linear Energy Transfer (LET) radiation.
  • To explore the correlation between radiosensitivity, HER2-targeted radionuclide uptake, and cellular characteristics.

Main Methods:

  • Utilized three HER2-overexpressing cell lines: SKOV-3, SKBR-3, and BT-474.
  • Assessed radiosensitivity using clonogenic survival and growth extrapolation assays after photon (low LET) irradiation.
  • Evaluated response to alpha particles (high LET) from (211)At decays, delivered via a HER2-binding affibody molecule ((211)At-(Z(HER2:4))(2)).
  • Studied affibody molecule internalization using specific assays.

Main Results:

  • Significant differences in radiosensitivity were observed among cell lines following photon irradiation, with SKOV-3 being most radioresistant and BT-474 most sensitive.
  • While HER2-dependent uptake of (211)At was similar across cell lines, sensitivity to alpha particle radiation varied.
  • SKOV-3 cells demonstrated the highest resistance, and BT-474 the highest sensitivity to alpha particles, correlating with affibody internalization and nuclear size.

Conclusions:

  • HER2-overexpressing breast cancer cells exhibit differential inherent radiosensitivity.
  • This variability in radiosensitivity, particularly to high-LET radiation, is influenced by affibody molecule internalization and cell nucleus size.
  • Findings have significant implications for both conventional radiotherapy and the development of HER2-targeted radionuclide therapies.